This is a massive insider buy from a major shareholder that should be read as a strong bullish signal. Traders should monitor for upcoming catalysts such as clinical trial updates or partnership announcements. Given the historical over-scoring on ARTV (past long calls have been wrong), size the position carefully and consider a price target aligned with the purchase range up to $8.99.
Price Chart
Executive Summary
RA Capital Management, a director and 10% owner, purchased 1.43 million shares of Artiva Biotherapeutics for $11.14 million across five open-market trades from June 9-12, 2026. The purchase represents approximately 4.9% of the company's $227 million market cap, a highly material insider buying signal that indicates strong conviction in the company's prospects.
Key Financial Metrics
Key Facts
- Total insider purchase of $11.14 million over 5 trades from June 9-12, 2026
- Purchase represents ~4.9% of $227M market cap, well above the 2% materiality threshold
- Only insider is RA Capital Management, L.P., acting as both director and 10% owner
- Prices ranged from $6.91 to $8.99 per share, with largest trades at higher prices
- Recent 30-day insider activity shows $12.3M in total buys vs $450K in sells, indicating net accumulation
Financial Impact
$11.14 million purchase, approximately 4.9% of market cap
Risk Factors
- Historical performance shows that prior bullish reports on ARTV have been wrong, with average T+20 loss of -12.37%
- Biotech single-product risk and clinical-stage volatility
- Insider could be buying to maintain ownership percentage ahead of dilution or strategic move
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000656 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access